MAP2K7 and neoplasm: Although it has long been known that the MEK-ERK pathway is involved in T cell signaling,7 the immunological effects of MEK inhibitors have mostly been studied in the context of anti-tumor immunity, where potential interference with checkpoint inhibitors could be detrimental.8